Depression and Suicidality in Patients with Left Ventricular Assist Devices and Advanced Cardiac Therapies: Mechanisms, Risk Factors, and Clinical Management
AI Summary
Depression affects ~20–42% of advanced heart failure patients; suicidal ideation occurs in up to 12% of LVAD recipients with increased suicide attempts.
Mechanisms include neurohormonal dysregulation, systemic inflammation, and psychological processes; risk factors span patient, disease, device, and psychosocial domains.
Routine mental health screening and integrated multidisciplinary care must be implemented; research should prioritise longitudinal assessment and standardised suicide risk monitoring.
Med Sci (Basel). 2026 May 7;14(2):244. doi: 10.3390/medsci14020244.
ABSTRACT
BACKGROUND: The increasing use of advanced cardiac surgical therapies, particularly left ventricular assist devices (LVADs), has improved survival in patients with end-stage heart failure. However, the psychological burden associated with these therapies-especially depression and suicidality-remains underrecognized.
OBJECTIVES: This narrative review synthesizes current evidence on the prevalence, underlying mechanisms, risk factors, screening strategies, and management of depression and suicidality in patients undergoing LVAD implantation and other advanced cardiac surgical interventions.
METHODS: A structured literature search of PubMed, Embase, and Scopus was conducted for studies published between 2020 and 2025 addressing depression, suicidal ideation, suicide attempts, and psychological distress in LVAD and advanced cardiac therapy populations.
RESULTS: Depression affects approximately 20-42% of patients with advanced heart failure, including those supported with LVADs, while suicidal ideation is reported in up to 12% of LVAD recipients, with higher rates of suicide attempts compared to other chronic disease populations. Risk factors are multifactorial and can be categorized into patient-related, disease-related, device-related, and psychosocial domains. Proposed mechanisms include neurohormonal dysregulation, systemic inflammation, and psychological processes such as loss of autonomy and existential distress. Although validated screening tools and multidisciplinary management strategies are available, their implementation in routine clinical practice remains inconsistent.
CONCLUSIONS: Depression and suicidality represent significant and complex challenges in patients undergoing advanced cardiac therapies, particularly LVAD support. Systematic mental health screening and integrated, multidisciplinary care models are essential to improve patient outcomes. Future research should focus on longitudinal assessment, standardized suicide risk monitoring, and the development of targeted, evidence-based interventions for this vulnerable population.
Omega (Westport). 2026 May 27:302228261455640. doi: 10.1177/00302228261455640. Online ahead of print.ABSTRACTDeath obsession is a common phenomenon in many societies. Adults may be more susceptible to...
World J Biol Psychiatry. 2026 May 27:1-44. doi: 10.1080/15622975.2026.2651738. Online ahead of print.ABSTRACTOBJECTIVE: To prepare evidence-based guidelines on psychosis prevention.METHODS: We reviewed evidence on risk...
JAMA Netw Open. 2026 May 1;9(5):e2615005. doi: 10.1001/jamanetworkopen.2026.15005.ABSTRACTIMPORTANCE: Intellectual and developmental disabilities (IDDs) include cognitive and adaptive deficits beginning before ages 18 to 22 years....
JAMA Psychiatry. 2026 May 27. doi: 10.1001/jamapsychiatry.2026.1064. Online ahead of print.ABSTRACTIMPORTANCE: Although both recurrent copy number variants (rCNVs) and polygenic scores (PGSs) impart risk for...
